By evaluating large bodies of evidence in a structured and transparent manner, Cochrane reviews provide insights that are not captured in a single study. Moreover, the reviews are living documents-as additional evidence emerges, reviews are periodically updated. This allows providers, patients, researchers, and policy makers to understand the latest developments, keeping pace with the rapidly changing landscape of medicine.
An early example of the impact of Cochrane reviews on health outcomes is illustrated in the logo.
The forest plot within the logo represents the summary results of a study on the effectiveness of oral corticosteroids administered to pregnant women prior to preterm delivery [1] . Although several clinical trials had previously been conducted, it was not until the publication of Cochrane's systematic review that this intervention became widely used, saving thousands of premature babies.
The CEV Group has also conducted impactful reviews of novel drug therapies for eye diseases. One excellent example is Cochrane's review of the use of anti-vascular endothelial growth factor (anti-VEGF) for neovascular age-related macular degeneration (AMD) [2] . Anti-VEGF agents are injected intravitreally and aim to prevent the growth of abnormal blood vessels in the back of the eye. Examining 12 randomized controlled trials involving a total of 5496 patients across five continents, Cochrane compared the three commercially available drugs at the time of the review (pegaptanib, ranibizumab, and bevacizumab). All three were found to have protective effects in neovascular AMD, but the latter two yielded larger improvements in visual acuity than pegaptanib. Furthermore, the authors noted that while there was little difference in therapeutic outcome between bevacizumab and ranibizumab, ranibizumab was considerably more costly.
Cochrane has also synthesized evidence on the efficacy of visual rehabilitation, the effects of different models of eye care, and the performance and accuracy of diagnostic tests for eye diseases. Besides influencing healthcare decision-making, such reviews often expose important gaps in knowledge, encouraging the conduct of primary research and informing future research directions.
Not all reviews are created equal. Regarding the increasing number of poor-quality systematic reviews that have been published in the literature, John Ionannadis, a highly cited researcher and expert on research methodology, has said, "… the large majority of produced systematic reviews and metaanalyses are unnecessary, misleading, and/or conflicted" [3] . The validity, trustworthiness, and relevance of Cochrane reviews are thus more important now than ever.
Beginning in February, Eye will feature Cochrane Eye and Vision reviews. Although Cochrane reviews were originally conceived as electronic publications, highlighting reviews in this journal will ensure wider readership. With enhanced distribution of Cochrane's critical insights into healthcare interventions, providers will be able to better implement evidence-based medicine and improve patient care.
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